Literature DB >> 11807299

Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression.

Victor Appay1, Pokrath Hansasuta, Julian Sutton, Rachel D Schrier, Joseph K Wong, Manohar Furtado, Diane V Havlir, Steven M Wolinsky, Andrew J McMichael, Douglas D Richman, Sarah L Rowland-Jones, Celsa A Spina.   

Abstract

DESIGN: Antiretroviral therapy (ART) currently represents the best way to avert the lethal consequences of chronic persistent HIV-1 infection. It leads to significant reductions of plasma viremia, often to undetectable levels, but it can also be linked with the reduction and disappearance of detectable HIV-specific CD8 T-cell responses.
RESULTS: Here we describe a group of patients in whom ongoing replication of HIV, particularly transcription of Nef mRNA species, was detected despite prolonged and clinically successful antiretroviral treatment. Modest, but significant, numbers of HIV-specific CD8 T cells and CD4 T-cell responses were found in these subjects, with the strongest responses directed towards Nef epitopes. Detailed phenotypic analysis of the HIV-specific CD8 cells demonstrated low perforin levels and persistent expression of CD27, a phenotype associated with incomplete differentiation of cytotoxic T lymphocytes (CTL).
CONCLUSION: This immature CTL phenotype has been described previously in association with chronic HIV disease, but its continued persistence is surprising in the setting of prolonged viral suppression on therapy and the presence of HIV-specific CD4 cell activity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11807299     DOI: 10.1097/00002030-200201250-00004

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  11 in total

Review 1.  Preserving HIV-specific T cell responses: does timing of antiretroviral therapy help?

Authors:  Bernard J C Macatangay; Charles R Rinaldo
Journal:  Curr Opin HIV AIDS       Date:  2015-01       Impact factor: 4.283

2.  Comparison between HIV- and CMV-specific T cell responses in long-term HIV infected donors.

Authors:  L Papagno; V Appay; J Sutton; T Rostron; G M A Gillespie; G S Ogg; A King; A T Makadzanhge; A Waters; C Balotta; A Vyakarnam; P J Easterbrook; S L Rowland-Jones
Journal:  Clin Exp Immunol       Date:  2002-12       Impact factor: 4.330

3.  CD8+ T cells fail to limit SIV reactivation following ART withdrawal until after viral amplification.

Authors:  Afam A Okoye; Derick D Duell; Yoshinori Fukazawa; Benjamin Varco-Merth; Alejandra Marenco; Hannah Behrens; Morgan Chaunzwa; Andrea N Selseth; Roxanne M Gilbride; Jason Shao; Paul T Edlefsen; Romas Geleziunas; Mykola Pinkevych; Miles P Davenport; Kathleen Busman-Sahay; Michael Nekorchuk; Haesun Park; Jeremy Smedley; Michael K Axthelm; Jacob D Estes; Scott G Hansen; Brandon F Keele; Jeffery D Lifson; Louis J Picker
Journal:  J Clin Invest       Date:  2021-04-15       Impact factor: 14.808

4.  T cell functionality in HIV-1, HIV-2 and dually infected individuals: correlates of disease progression and immune restoration.

Authors:  S Salwe; V Padwal; V Nagar; P Patil; V Patel
Journal:  Clin Exp Immunol       Date:  2019-07-18       Impact factor: 4.330

5.  Combination Immune Checkpoint Blockade Enhances IL-2 and CD107a Production from HIV-Specific T Cells Ex Vivo in People Living with HIV on Antiretroviral Therapy.

Authors:  Chris Y Chiu; Judy J Chang; Ashanti I Dantanarayana; Ajantha Solomon; Vanessa A Evans; Rachel Pascoe; Céline Gubser; Lydie Trautman; Rémi Fromentin; Nicolas Chomont; James H McMahon; Paul U Cameron; Thomas A Rasmussen; Sharon R Lewin
Journal:  J Immunol       Date:  2021-12-01       Impact factor: 5.422

6.  Transcriptional suppression of in vitro-integrated human immunodeficiency virus type 1 does not correlate with proviral DNA methylation.

Authors:  Marjorie Pion; Albert Jordan; Angelique Biancotto; Franck Dequiedt; Françoise Gondois-Rey; Sophie Rondeau; Robert Vigne; Jiri Hejnar; Eric Verdin; Ivan Hirsch
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Differences in HIV-specific T cell responses between HIV-exposed and -unexposed HIV-seronegative individuals.

Authors:  Adam J Ritchie; Suzanne L Campion; Jakub Kopycinski; Zoe Moodie; Z Maggie Wang; Kruti Pandya; Stephen Moore; Michael K P Liu; Simon Brackenridge; Kristin Kuldanek; Kenneth Legg; Myron S Cohen; Eric L Delwart; Barton F Haynes; Sarah Fidler; Andrew J McMichael; Nilu Goonetilleke
Journal:  J Virol       Date:  2011-01-26       Impact factor: 5.103

8.  CD8 T-Cell Responses before and after Structured Treatment Interruption in Ugandan Adults Who Initiated ART with CD4 T Cells <200 Cell/μL: The DART Trial STI Substudy.

Authors:  Jennifer Serwanga; Susan Mugaba; Auma Betty; Edward Pimego; Sarah Walker; Paula Munderi; Charles Gilks; Frances Gotch; Heiner Grosskurth; Pontiano Kaleebu
Journal:  AIDS Res Treat       Date:  2011-01-18

9.  A double-blind randomized phase I clinical trial targeting ALVAC-HIV vaccine to human dendritic cells.

Authors:  Michael A Eller; Bonnie M Slike; Josephine H Cox; Emil Lesho; Zhining Wang; Jeffrey R Currier; Janice M Darden; Victoria R Polonis; Maryanne T Vahey; Sheila Peel; Merlin L Robb; Nelson L Michael; Mary A Marovich
Journal:  PLoS One       Date:  2011-09-16       Impact factor: 3.240

10.  Do HIV-specific CTL continue to have an antiviral function during antiretroviral therapy? If not, why not, and what can be done about it?

Authors:  Dorian McIlroy
Journal:  Front Immunol       Date:  2013-03-01       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.